Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic

[1]  Scott Sloka,et al.  Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination , 2012, Annals of neurology.

[2]  Robert G. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2012, The Cochrane database of systematic reviews.

[3]  Christilyn P. Graff,et al.  Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[5]  Paola Piccini,et al.  Priorities in Parkinson's disease research , 2011, Nature Reviews Drug Discovery.

[6]  B. Trapp,et al.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis , 2011, Progress in Neurobiology.

[7]  Wutian Wu,et al.  LINGO‐1 negatively regulates TrkB phosphorylation after ocular hypertension , 2010, The European journal of neuroscience.

[8]  Jun Lv,et al.  Passive Immunization with LINGO-1 Polyclonal Antiserum Afforded Neuroprotection and Promoted Functional Recovery in a Rat Model of Spinal Cord Injury , 2010, Neuroimmunomodulation.

[9]  C. Brosnan,et al.  Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination , 2009, Proceedings of the National Academy of Sciences.

[10]  H. Yip,et al.  Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma , 2009, Neuroscience.

[11]  D. Rowitch,et al.  Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. , 2009, Genes & development.

[12]  A. Chédotal,et al.  Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells , 2009, Annals of neurology.

[13]  R. Rudick,et al.  LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence , 2008, Expert opinion on biological therapy.

[14]  Wutian Wu,et al.  Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. , 2008, Investigative ophthalmology & visual science.

[15]  A. Sandrock,et al.  LINGO-1 and its role in CNS repair. , 2008, The international journal of biochemistry & cell biology.

[16]  Li Wang,et al.  LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis , 2007, Nature Medicine.

[17]  T. Engber,et al.  Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models , 2007, Proceedings of the National Academy of Sciences.

[18]  S. Lacroix,et al.  Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system , 2007, Molecular and Cellular Neuroscience.

[19]  M. Tuszynski,et al.  Nerve Growth Factor Gene Therapy in Alzheimer Disease , 2007, Alzheimer disease and associated disorders.

[20]  J. Chan,et al.  NGF Regulates the Expression of Axonal LINGO-1 to Inhibit Oligodendrocyte Differentiation and Myelination , 2007, The Journal of Neuroscience.

[21]  J. Schmier,et al.  The economic implications of glaucoma: a literature review. , 2007, PharmacoEconomics.

[22]  J. Relton,et al.  LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury , 2006, Molecular and Cellular Neuroscience.

[23]  S. Hauser,et al.  The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.

[24]  A. Granholm,et al.  Nerve growth factor in treatment and pathogenesis of Alzheimer's disease , 2006, Progress in Neurobiology.

[25]  Z. Sahenk.  Neurotrophins and Peripheral Neuropathies , 2006, Brain pathology.

[26]  B. Tang,et al.  AMIGO and friends: An emerging family of brain-enriched, neuronal growth modulating, type I transmembrane proteins with leucine-rich repeats (LRR) and cell adhesion molecule motifs , 2006, Brain Research Reviews.

[27]  D. Pham‐Dinh,et al.  Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat , 2006, Experimental Neurology.

[28]  A. Lang,et al.  Crossroads in GDNF therapy for Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[29]  Chao Zhao,et al.  Myelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation , 2006, The Journal of Neuroscience.

[30]  C. Lundberg,et al.  Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease , 2005, The European journal of neuroscience.

[31]  T. Okafuji,et al.  Expression pattern of LINGO-1 in the developing nervous system of the chick embryo. , 2005, Gene expression patterns : GEP.

[32]  M. Lavail.  Survival factors for treatment of retinal degenerative disorders: preclinical gains and issues for translation into clinical studies. , 2005, Retina.

[33]  Mahendra S Rao,et al.  Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation , 2005, Nature Medicine.

[34]  B. Trapp,et al.  LINGO-1 negatively regulates myelination by oligodendrocytes , 2005, Nature Neuroscience.

[35]  A. Kakita,et al.  Influences of dopaminergic lesion on epidermal growth factor‐ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons , 2005, Journal of neurochemistry.

[36]  Zhigang He,et al.  A TNF Receptor Family Member, TROY, Is a Coreceptor with Nogo Receptor in Mediating the Inhibitory Activity of Myelin Inhibitors , 2005, Neuron.

[37]  John M. McCoy,et al.  TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration , 2005, Neuron.

[38]  J. Pohl,et al.  Heparin-binding epidermal growth factor-like growth factor: a component in chromaffin granules which promotes the survival of nigrostriatal dopaminergic neurones in vitro and in vivo , 2004, Neuroscience.

[39]  E. Shooter,et al.  NGF Controls Axonal Receptivity to Myelination by Schwann Cells or Oligodendrocytes , 2004, Neuron.

[40]  P. Bongioanni,et al.  Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. , 2004, The Cochrane database of systematic reviews.

[41]  Jian Zhang,et al.  Ciliary neurotrophic factor for acceleration of peripheral nerve regeneration: an experimental study. , 2004, Journal of reconstructive microsurgery.

[42]  J. Relton,et al.  LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex , 2004, Nature Neuroscience.

[43]  C. Sotelo,et al.  Multiple Roles for Slits in the Control of Cell Migration in the Rostral Migratory Stream , 2004, The Journal of Neuroscience.

[44]  W. Richardson,et al.  Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination , 2004, Molecular and Cellular Neuroscience.

[45]  V. Gallai†,et al.  Nerve growth factor and chronic daily headache: a potential implication for therapy , 2004, Expert review of neurotherapeutics.

[46]  X. Estivill,et al.  LRRN6A/LERN1 (leucine‐rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex , 2003, The European journal of neuroscience.

[47]  S. Strittmatter,et al.  The Nogo-66 receptor: focusing myelin inhibition of axon regeneration , 2003, Trends in Neurosciences.

[48]  J. Kuja-Panula,et al.  AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats , 2003, The Journal of cell biology.

[49]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[50]  Robin J. M. Franklin,et al.  Why does remyelination fail in multiple sclerosis? , 2002, Nature Reviews Neuroscience.

[51]  R. Franklin.  Remyelination of the demyelinated CNS: the case for and against transplantation of central, peripheral and olfactory glia , 2002, Brain Research Bulletin.

[52]  R. Rudick,et al.  Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. , 2002, The New England journal of medicine.

[53]  A. Fournier,et al.  Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration , 2001, Nature.

[54]  N. Holbrook,et al.  Epidermal Growth Factor Receptor-dependent Akt Activation by Oxidative Stress Enhances Cell Survival* , 2000, The Journal of Biological Chemistry.

[55]  R. Franklin,et al.  Understanding CNS remyelination: Clues from developmental and regeneration biology , 1999, Journal of neuroscience research.

[56]  R. Pallini.  Anatomy of "Regenerating Axons" , 1998, Science.

[57]  J. del Río,et al.  [Neurotrophins. II: therapeutic potential]. , 1997, Revista de medicina de la Universidad de Navarra.

[58]  D. Zack,et al.  Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. , 1995, Investigative ophthalmology & visual science.

[59]  David C. Lee,et al.  Expression of EGF receptor mRNA in rat nigrostriatal system , 1994, Neuroreport.